Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) EBT Margin (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed EBT Margin for 16 consecutive years, with 241.07% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin changed N/A to 241.07% in Q3 2025 year-over-year; TTM through Sep 2025 was 235.51%, a 24341.0% decrease, with the full-year FY2024 number at 73.85%, changed N/A from a year prior.
  • EBT Margin was 241.07% for Q3 2025 at NovaBay Pharmaceuticals, down from 9.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 263.3% in Q4 2023 to a low of 241.07% in Q3 2025.
  • A 5-year average of 41.3% and a median of 55.71% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 19737bps in 2023, then plummeted -27318bps in 2024.
  • NovaBay Pharmaceuticals' EBT Margin stood at 3.57% in 2021, then surged by 1946bps to 65.93% in 2022, then surged by 299bps to 263.3% in 2023, then crashed by -104bps to 9.87% in 2024, then tumbled by -2341bps to 241.07% in 2025.
  • Per Business Quant, the three most recent readings for NBY's EBT Margin are 241.07% (Q3 2025), 9.87% (Q4 2024), and 50.05% (Q2 2024).